Managing cancer and living meaningfully (CALM) in adults with malignant glioma: a proof-of-concept phase IIa trial.
Managing cancer and living meaningfully (CALM) in adults with malignant glioma: a proof-of-concept phase IIa trial.
复制标题
DOI：
10.1007/s11060-022-03988-8
复制
发表时间：
2022-05
影响因子：
3.9
通讯作者：
Thacker, Leroy
中科院分区：
文献类型：
--
作者：
Loughan, Ashlee R.;Willis, Kelcie D.;Braun, Sarah Ellen;Rodin, Gary;Lanoye, Autumn;Davies, Alexandria E.;Svikis, Dace;Mazzeo, Suzanne;Malkin, Mark;Thacker, Leroy
管理癌症和有意义地生活(平静)是一种以证据为基础的、简短的、半结构化的心理疗法，旨在帮助晚期癌症患者应对其疾病的实际和深刻的挑战。然而，到目前为止，还没有研究调查其在成人恶性胶质瘤患者中的可行性、可接受性和初步有效性，尽管在这一脆弱和服务不足的人群中有很好的心理困扰发生率。14名有抑郁和/或死亡焦虑症状升高的胶质瘤患者参加了试验：83%为胶质母细胞瘤，75%为女性，MAGE=56岁(SD=15.1；范围=27-81)。根据已建立的指标对可行性进行了评估。可接受性通过会后调查和干预后访谈来衡量。初步干预效果采用配对t检验，比较干预前和干预后的心理困扰。在14名入选的患者中，12名是可评估的。其中9人完成了研究(保留率为75%)。三名患者由于疾病的实质性进展而退出，这影响了他们参与的能力。参与者报告了很高的感知收益，并都向其他人推荐了该计划。干预后评估的基线显示死亡焦虑、广泛性焦虑和抑郁的减少，以及灵性的增加。在整个研究期间，生活质量和对癌症复发的恐惧保持稳定。对于患有恶性胶质瘤的成人患者，CAMPE似乎是可行的。登记和保留率很高，可以与晚期癌症患者的心理治疗试验相媲美。参与者报告了死亡焦虑、广泛性焦虑和抑郁的高感知收益和症状的减少。这些发现非常鼓舞人心，并支持神经肿瘤学中对CAMPE的进一步研究。
Managing Cancer and Living Meaningfully (CALM) is an evidence-based, brief, semi-structured psychotherapy designed to help patients with advanced cancer cope with the practical and profound challenges of their illness. However, no study to date has investigated its feasibility, acceptability, and preliminary effectiveness in adults with malignant glioma, despite the well-documented incidence of psychological distress in this vulnerable and underserved population. Fourteen patients with glioma and elevated symptoms of depression and/or death anxiety enrolled in the trial: 83% glioblastoma, 75% female, Mage = 56 years (SD = 15.1; range = 27–81). Feasibility was assessed based on established metrics. Acceptability was measured by post-session surveys and post-intervention interviews. Preliminary intervention effects were explored using paired t-tests, comparing psychological distress at baseline and post-intervention. Of the 14 enrolled patients, 12 were evaluable. Nine completed the study (75% retention rate). Three patients withdrew due to substantial disease progression which affected their ability to participate. Participants reported high perceived benefit, and all recommended the program to others. Baseline to post-intervention assessments indicated reductions in death anxiety, generalized anxiety, and depression, and increases in spirituality. Quality of life and fear of cancer recurrence remained stable throughout the study period. CALM appears feasible for use with adults with malignant glioma. Enrollment and retention rates were high and comparable to psychotherapy trials for patients with advanced cancer. High perceived benefit and reductions in symptoms of death anxiety, generalized anxiety, and depression were reported by participants. These findings are extremely encouraging and support further study of CALM in neuro-oncology.
登录
查看更多内容
DOI：
10.1007/s10880-019-09690-8
发表时间：
2019-12-17
影响因子：
2.2
作者：
Loughan, Ashlee R.;Lanoye, Autumn;Braun, Sarah
通讯作者：
Braun, Sarah
影响因子：
45.3
作者：
Gehring, Karin;Sitskoorn, Margriet M.;Aaronson, Neil K.
通讯作者：
Aaronson, Neil K.
影响因子：
3.9
作者：
Braun, Sarah Ellen;Aslanzadeh, Farah J.;Lanoye, Autumn;Fountain-Zaragoza, Stephanie;Malkin, Mark G.;Loughan, Ashlee R.
通讯作者：
Loughan, Ashlee R.
影响因子：
8.4
作者：
Lo, Christopher;Burman, Debika;Zimmermann, Camilla
通讯作者：
Zimmermann, Camilla
影响因子：
4.2
作者：
Czajkowski, Susan M.;Powell, Lynda H.;Charlson, Mary E.
通讯作者：
Charlson, Mary E.